Answers are grounded in this paper and cite their sources.
Systematic review compares early mortality outcomes in acute myeloid leukemia with and without leukapheresis, suggesting minimal benefit.
INTRODUCTION: Leukapheresis is used for rapid cytoreduction in adults with acute myeloid leukemia (AML) and hyperleukocytosis, but its effect on early mortality remains uncertain. We performed an updated systematic review and meta-analysis of comparative studies. METHODS: MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, and citation searching were searched from inception to March 2026. Comparative studies of leukapheresis versus no leukapheresis in adults with AML and hyperleukocytosis were included. Risk of bias was assessed using ROBINS-I, and certainty of evidence was assessed using GRADE. Random-effects meta-analysis of crude 2 × 2 data was performed using odds ratios (ORs). Only one study reported an adjusted estimate. Most studies were at serious risk of bias, and certainty of evidence was very low. CONCLUSIONS: Current non-randomized evidence does not establish a reliable early-mortality benefit of leukapheresis. Confounding by indication remains a major limitation. REGISTRATION: This study was prospectively registered on PROSPERO (identifier: CRD420261351743).
No takes yet. Share an insight, caveat, or question.
Reyes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: